Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Prader-Willi syndrome (PWS) is a rare genetic disease caused by imprinted gene dysfunction, typically involving deletion of the chromosome 15q11.2-q13 region, balanced translocation, or related gene mutations in this region. PWS presents with complex and varied clinical manifestations. Abnormalities can be observed from the fetal stage and change with age, resulting in growth, developmental, and metabolic issues throughout different life stages. We report the prenatal characteristics observed from the second to third trimester of pregnancy in a neonate with PWS. Prenatal ultrasound findings included a single umbilical artery, poor abdominal circumference growth from 26 weeks, normal head circumference and femur length growth, increased amniotic fluid volume after 30 weeks, undescended fetal testicles in the third trimester, small kidneys, and reduced fetal movement. The male infant was born at 38 weeks of gestation with a birth weight of 2580 g. He had a weak cry; severe hypotonia; small eyelid clefts; bilateral cryptorchidism; low responsiveness to medical procedures such as blood drawing; and poor sucking, necessitating tube feeding. Blood methylation-specific multiple ligation-dependent probe amplification (MS-MLPA) showed paternal deletion PWS. Notably, this case revealed two previously unreported prenatal features in PWS: a single umbilical artery and small kidneys. Through literature review and our case presentation, we suggest that a combination of specific sonographic features, including these newly identified markers, may aid clinicians in the early diagnosis of PWS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12249360PMC
http://dx.doi.org/10.3390/diagnostics15131666DOI Listing

Publication Analysis

Top Keywords

prader-willi syndrome
8
literature review
8
third trimester
8
single umbilical
8
umbilical artery
8
small kidneys
8
pws
6
prenatal
4
prenatal phenotype
4
phenotype neonate
4

Similar Publications

Sleep disorder assessment in children and adolescents with neurodevelopmental disorders.

J Pediatr (Rio J)

September 2025

Escola de Medicina da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil; Instituto do Cérebro (InsCer), Porto Alegre, RS, Brazil. Electronic address:

Objective: To review the associations between various neurodevelopmental disorders and the most prevalent sleep disorders in children and adolescents, focusing on clinical characteristics and diagnostic approaches.

Data Sources: A literature review was conducted using the PubMed database, employing the search terms "neurodevelopmental disorders" and "sleep disorders," including "insomnia," "sleep-related breathing disorders," "circadian rhythm sleep-wake disorders," "sleep-related movement disorders," "parasomnias," and "central disorders of hypersomnolence." Specific diagnostic terms related to neurodevelopmental and sleep disorders were also utilized.

View Article and Find Full Text PDF

Background: Prader-Willi syndrome (PWS) is a complex genetic disorder characterised by infantile hypotonia, early-onset obesity, intellectual disability, hypopigmentation, small hands and feet, short stature, hypogonadism, and distinctive facial features.

Aim: To generate and report growth curves for height, sitting height, hands and feet length for Argentine children with Prader-Willi syndrome (PWS) without growth hormone treatment.

Subjects And Methods: A total of 1174 anthropometric measures were obtained from 167 children (82 boys) aged 0-19 years attending Hospital Garrahan between 1992 and 2019.

View Article and Find Full Text PDF

Objective: The melanocortin-4 receptor agonist setmelanotide has demonstrated effectiveness in phase 3 clinical trials for patients with monogenic obesity caused by biallelic variants in the leptin receptor (LEPR) and pro-opiomelanocortin (POMC), as well as for individuals with Bardet-Biedl syndrome (BBS). However, real-world evidence remains limited. This study evaluates the long-term effectiveness and safety of setmelanotide in patients who received treatment under a pre-marketing early-access authorization.

View Article and Find Full Text PDF